CL2015003602A1 - Composiciones y métodos para tratar anemia. - Google Patents
Composiciones y métodos para tratar anemia.Info
- Publication number
- CL2015003602A1 CL2015003602A1 CL2015003602A CL2015003602A CL2015003602A1 CL 2015003602 A1 CL2015003602 A1 CL 2015003602A1 CL 2015003602 A CL2015003602 A CL 2015003602A CL 2015003602 A CL2015003602 A CL 2015003602A CL 2015003602 A1 CL2015003602 A1 CL 2015003602A1
- Authority
- CL
- Chile
- Prior art keywords
- treat anemia
- compositions
- methods
- hif
- alfa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
FORMA DE DOSIFICACION QUE COMPRENDE ACIDO {[5-(3-CLOROFENIL)-3-HIDROXIPIRIDIN-2-CARBONIL]AMINO}-ACETICO; USO PARA TRATAR ANEMIA; METODO PARA TRATAR ANEMIA; USO DE UN INHIBIDOR DE HIF PROLIL HIDROXILASA O ESTABILIZADOR DE HIF-ALFA; USO PARA INCREMENTAR LA PRODUCCION DE EPO ENDOGENA E INDUCIR RESPUESTA; COMPOSICION FARMACEUTICA.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL2018002372A CL2018002372A1 (es) | 2013-06-13 | 2018-08-17 | Composiciones y métodos para tratar anemia (divisional solicitud 201503602) |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361834808P | 2013-06-13 | 2013-06-13 | |
US201361889478P | 2013-10-10 | 2013-10-10 | |
US201361898885P | 2013-11-01 | 2013-11-01 | |
US201361898890P | 2013-11-01 | 2013-11-01 | |
US201361912185P | 2013-12-05 | 2013-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015003602A1 true CL2015003602A1 (es) | 2016-07-29 |
Family
ID=52022903
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015003602A CL2015003602A1 (es) | 2013-06-13 | 2015-12-11 | Composiciones y métodos para tratar anemia. |
CL2018002372A CL2018002372A1 (es) | 2013-06-13 | 2018-08-17 | Composiciones y métodos para tratar anemia (divisional solicitud 201503602) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018002372A CL2018002372A1 (es) | 2013-06-13 | 2018-08-17 | Composiciones y métodos para tratar anemia (divisional solicitud 201503602) |
Country Status (29)
Country | Link |
---|---|
US (1) | US11857543B2 (es) |
EP (2) | EP4360706A2 (es) |
JP (5) | JP2016521747A (es) |
KR (4) | KR102461176B1 (es) |
CN (3) | CN114404414A (es) |
AU (3) | AU2014278543B2 (es) |
BR (1) | BR112015031027A2 (es) |
CA (2) | CA3151685A1 (es) |
CL (2) | CL2015003602A1 (es) |
DK (1) | DK3007695T3 (es) |
DO (1) | DOP2015000297A (es) |
EC (1) | ECSP20058592A (es) |
FI (1) | FI3007695T3 (es) |
HK (1) | HK1216844A1 (es) |
HR (1) | HRP20240319T1 (es) |
IL (3) | IL243047B (es) |
LT (1) | LT3007695T (es) |
MX (3) | MX2015017229A (es) |
NZ (3) | NZ753905A (es) |
PE (2) | PE20160194A1 (es) |
PH (2) | PH12015502738A1 (es) |
PT (1) | PT3007695T (es) |
RS (1) | RS65341B1 (es) |
RU (2) | RU2705206C2 (es) |
SG (2) | SG10201910773VA (es) |
SI (1) | SI3007695T1 (es) |
TW (4) | TWI650126B (es) |
WO (1) | WO2014200773A2 (es) |
ZA (1) | ZA201509024B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2327696A1 (en) | 2006-06-26 | 2011-06-01 | Warner Chilcott Company, LLC | Prolyl hydroxylase inhibitors and methods of use |
NO2686520T3 (es) | 2011-06-06 | 2018-03-17 | ||
JP6608355B2 (ja) | 2013-04-16 | 2019-11-20 | コーニンクレッカ フィリップス エヌ ヴェ | 表面ecgにおける両心室ペースメーカパルス検出のためのシステム及び方法 |
NZ753905A (en) | 2013-06-13 | 2020-07-31 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
TWI788702B (zh) | 2013-11-15 | 2023-01-01 | 美商阿克比治療有限公司 | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途 |
AU2016209126A1 (en) | 2015-01-23 | 2017-08-10 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
US11324734B2 (en) * | 2015-04-01 | 2022-05-10 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
WO2018103600A1 (zh) * | 2016-12-06 | 2018-06-14 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的杂芳基酰胺化合物及包含该化合物的组合物及其用途 |
WO2019028150A1 (en) * | 2017-08-01 | 2019-02-07 | Akebia Therapeutics, Inc. | COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES |
US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
AU2020374963A1 (en) | 2019-10-31 | 2022-06-09 | Akebia Therapeutics, Inc. | Therapeutic methods using vadadustat |
US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
WO2021186356A1 (en) * | 2020-03-17 | 2021-09-23 | Cadila Healthcare Limited | Formulation comprising hif prolyl hydroxylase inhibitors |
WO2021222424A1 (en) * | 2020-04-29 | 2021-11-04 | BioAge Labs, Inc. | Hypoxia-inducible factor prolyl hydroxylase inhibitors for treating aging-related conditions |
EP4181873A1 (en) | 2020-06-19 | 2023-05-24 | Akebia Therapeutics Inc. | Modulation of drug-drug interactions of vadadustat |
WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
AU2022206302A1 (en) | 2021-01-08 | 2023-08-17 | Akebia Therapeutics, Inc. | Therapeutic methods using vadadustat |
JP2024510926A (ja) | 2021-03-01 | 2024-03-12 | アケビア セラピューティクス インコーポレイテッド | バダデュスタットの薬物間相互作用の調節 |
Family Cites Families (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3655679A (en) | 1969-06-25 | 1972-04-11 | Merck & Co Inc | Certain aryl pyridine carboxylic acid derivatives |
US3703582A (en) | 1970-04-20 | 1972-11-21 | Merck & Co Inc | Aryl pyridine carboxylic acids in the treatment of inflammation |
US3894920A (en) | 1971-12-21 | 1975-07-15 | Sagami Chem Res | Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives |
US4016287A (en) | 1972-07-17 | 1977-04-05 | Boehringer Ingelheim Gmbh | Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof |
CA1261335A (en) * | 1984-08-29 | 1989-09-26 | Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee | Ethylenediamine monoamide derivatives |
CN1023479C (zh) | 1985-09-27 | 1994-01-12 | 弗·哈夫曼-拉罗切有限公司 | 乙二胺的单酰胺衍生物的制备方法 |
TW219933B (es) | 1990-02-26 | 1994-02-01 | Lilly Co Eli | |
US5405613A (en) | 1991-12-11 | 1995-04-11 | Creative Nutrition Canada Corp. | Vitamin/mineral composition |
TW352384B (en) | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
DE4219158A1 (de) | 1992-06-11 | 1993-12-16 | Thomae Gmbh Dr K | Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DK0650961T3 (da) | 1993-11-02 | 1997-09-15 | Hoechst Ag | Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler. |
DE59401923D1 (de) | 1993-11-02 | 1997-04-10 | Hoechst Ag | Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
DE4410480A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE4410423A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US5789426A (en) | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
DE19535571A1 (de) | 1995-09-14 | 1997-03-20 | Boehringer Mannheim Gmbh | Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten |
IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
JPH09221476A (ja) | 1995-12-15 | 1997-08-26 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
WO1997041103A1 (de) | 1996-04-30 | 1997-11-06 | Hoechst Aktiengesellschaft | 3-alkoxypyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel |
DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
DE19650215A1 (de) | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
US6420427B1 (en) | 1997-10-09 | 2002-07-16 | Ono Pharmaceutical Co., Ltd. | Aminobutyric acid derivatives |
DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
JP4495339B2 (ja) | 1998-03-23 | 2010-07-07 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ピペリジニルおよびn−アミジノピペリジニル誘導体 |
GB9809213D0 (en) | 1998-04-29 | 1998-07-01 | Glaxo Group Ltd | Pharmaceutical compositions |
US6177101B1 (en) | 1998-06-11 | 2001-01-23 | Pharmacia & Upjohn Company | Delavirdine high strength tablet formulation |
US6159379A (en) | 1999-05-04 | 2000-12-12 | Baker Hughes Incorporated | Organic ammonium salts for the removal of water soluble organics in produced water |
JP2001048786A (ja) | 1999-08-05 | 2001-02-20 | Yamanouchi Pharmaceut Co Ltd | 三環式ヘテロアリール誘導体 |
US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
CA2725833A1 (en) * | 2001-01-12 | 2002-07-18 | Sun Pharmaceutical Industries Limited | Spaced drug delivery system |
US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
US6849718B2 (en) | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
EP1379630B1 (en) | 2001-03-21 | 2012-09-26 | Isis Innovation Limited | Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
SE0101327D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | New crystalline forms |
US6566088B1 (en) | 2001-10-04 | 2003-05-20 | Board Of Regents, The University Of Texas System | Prolyl-4-hydroxylases |
GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
CA3094774A1 (en) | 2001-12-06 | 2003-07-03 | Fibrogen, Inc. | Use of hif prolyl hydroxylase inhibitors for treating neurological disorders |
NZ536908A (en) | 2002-05-17 | 2008-09-26 | Celgene Corp | Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient |
WO2003101431A1 (en) * | 2002-06-04 | 2003-12-11 | J.B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical composition for controlled drug delivery system |
WO2004019868A2 (en) | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | N-biarylmethyl aminocycloalkanecarboxamide derivatives |
PL376770A1 (pl) | 2002-10-16 | 2006-01-09 | Isis Innovation Limited | Hydroksylazy asparaginylowe i ich modulatory |
WO2004048383A1 (en) | 2002-11-21 | 2004-06-10 | Eli Lilly And Company | Mixed lineage kinase modulators |
US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
BRPI0411055B1 (pt) | 2003-06-06 | 2018-08-21 | Fibrogen, Inc | Compostos de heteroarilas contendo nitrogênio. seus usos no aumento da eritropoietina endógena, composição farmacêutica que os compreende e método in vitro de inibição da atividade da enzima hidrolase |
US8614204B2 (en) * | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
WO2005007192A2 (en) | 2003-06-06 | 2005-01-27 | Fibrogen, Inc. | Cytoprotection through the use of hif hydroxylase inhibitors |
GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
DE602005016800D1 (de) | 2004-05-28 | 2009-11-05 | Fibrogen Inc | Hif-prolylhydroxylase-aktivitätstest |
EP1771418A2 (en) | 2004-05-31 | 2007-04-11 | Tanabe Seiyaku Co., Ltd. | Large conductance calcium-activated k channel opener |
JP2008506702A (ja) | 2004-07-14 | 2008-03-06 | ピーティーシー セラピューティクス,インコーポレーテッド | C型肝炎を治療するための方法 |
TW200616969A (en) | 2004-09-17 | 2006-06-01 | Tanabe Seiyaku Co | Imidazole compound |
WO2006084210A2 (en) | 2005-02-04 | 2006-08-10 | Regents Of The University Of California, San Diego | Hif modulating compounds and methods of use thereof |
DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
US20060276477A1 (en) | 2005-06-06 | 2006-12-07 | Fibrogen, Inc. | Treatment method for anemia |
AU2006259352A1 (en) | 2005-06-15 | 2006-12-28 | Fibrogen, Inc. | Use of HIF 1alfa modulators for treatment of cancer |
WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
SI1928409T1 (sl) | 2005-09-12 | 2012-12-31 | Actelion Pharmaceuticals Ltd. | Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid |
WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
WO2007047194A2 (en) | 2005-10-11 | 2007-04-26 | Dana-Farber Cancer Institute, Inc. | Methods for treating mitf-related disorders |
EP1960363B1 (en) | 2005-12-09 | 2014-01-22 | Amgen, Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions and uses thereof |
JP2009522383A (ja) | 2006-01-09 | 2009-06-11 | ビーティージー・インターナショナル・リミテッド | 低酸素誘導因子−1の調節物質及び関連する使用 |
WO2007082899A1 (en) | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
JP4801451B2 (ja) | 2006-01-19 | 2011-10-26 | 株式会社日立ハイテクノロジーズ | 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法 |
WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
ITMI20060179A1 (it) | 2006-02-02 | 2007-08-03 | Abiogen Pharma Spa | Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse |
WO2007101204A1 (en) | 2006-02-27 | 2007-09-07 | Alcon Research, Ltd. | Method of treating glaucoma |
AR059733A1 (es) | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
JP2009537558A (ja) | 2006-05-16 | 2009-10-29 | スミスクライン・ビーチャム・コーポレイション | プロリルヒドロキシラーゼ阻害剤 |
KR100798730B1 (ko) * | 2006-06-12 | 2008-01-29 | 신풍제약주식회사 | 록소프로펜 또는 잘토프로펜 함유 제어방출성 제제 및 그의제조방법 |
AR061570A1 (es) | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto |
EP2327696A1 (en) * | 2006-06-26 | 2011-06-01 | Warner Chilcott Company, LLC | Prolyl hydroxylase inhibitors and methods of use |
CA2563690C (en) | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
GB2444904B (en) | 2006-12-05 | 2008-11-05 | Michael Hilary Burke | A Process For The Preparation of an Orally Administrable Unit Dose Tablet |
TW200845994A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: prolyl hydroxylase inhibitors |
TW200845991A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
RU2465900C2 (ru) | 2007-04-17 | 2012-11-10 | Рациофарм Гмбх | Фармацевтические композиции, содержащие ирбесартан |
WO2008130508A1 (en) | 2007-04-18 | 2008-10-30 | Amgen Inc. | Indanone derivatives that inhibit prolyl hydroxylase |
CA2683758A1 (en) | 2007-04-18 | 2008-10-30 | Merck & Co., Inc. | Novel 1,8-naphthyridine compounds |
AU2008248234B2 (en) | 2007-05-04 | 2011-02-03 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
CN101678011B (zh) | 2007-05-16 | 2012-07-18 | 默沙东公司 | 螺氮茚酮化合物 |
BRPI0812361A2 (pt) | 2007-05-18 | 2015-02-03 | Bayer Schering Pharma Ag | Derivados de pirazol heteroaril-substituídos úteis parao tratamento de distúrbios e doenças hiperproliferativos associados à angiogênese |
EP2186528B1 (en) | 2007-08-06 | 2014-03-19 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor |
TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
US20110028507A1 (en) | 2007-08-10 | 2011-02-03 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
WO2009035534A2 (en) | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
WO2009043093A1 (en) | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Hif inhibition |
WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
WO2009067790A1 (en) | 2007-11-26 | 2009-06-04 | Uti Limited Partnership | STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION |
US20100305154A1 (en) | 2007-11-30 | 2010-12-02 | Glaxosmithkline Llc | Prolyl Hydroxylase Inhibitors |
CN101983384A (zh) | 2007-11-30 | 2011-03-02 | 葛兰素史密斯克莱有限责任公司 | 脯氨酰羟化酶抑制剂 |
WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
EP2240178A4 (en) | 2007-12-19 | 2011-10-26 | Glaxosmithkline Llc | PROLYLHYDROXYLASEHEMMER |
WO2009086592A1 (en) | 2008-01-04 | 2009-07-16 | Garvan Institute Of Medical Research | Method of increasing metabolism |
EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
BRPI0909037B8 (pt) | 2008-03-03 | 2021-05-25 | Irm Llc | compostos moduladores da atividade de tlr, e composição farmacêutica |
AU2009273327A1 (en) | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
TW201006473A (en) * | 2008-08-13 | 2010-02-16 | Orient Pharma Co Ltd | Bi-layer medicine tablet containing Zaleplon |
EP2324006B1 (en) | 2008-09-15 | 2014-08-13 | Kasina Laila Innova Pharmaceuticals Private Ltd. | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers |
HU230877B1 (hu) * | 2008-09-30 | 2018-11-29 | EGIS Gyógyszergyár NyR | Stabil kombinációs gyógyszerkészítmény |
EP2370422B1 (en) | 2008-11-14 | 2019-06-05 | Fibrogen, Inc. | Thiochromene derivatives as hif hydroxylase inhibitors |
US8137666B2 (en) * | 2008-11-22 | 2012-03-20 | Academia Sinica | Nattokinase for degrading and reducing amyloid fibrils—associated with alzheimer's disease, prion diseases and other amyloidoses |
ES2429148T3 (es) | 2009-03-31 | 2013-11-13 | Kissei Pharmaceutical Co., Ltd. | Derivado de indolizina y su utilización para fines médicos |
ES2811342T3 (es) | 2009-03-31 | 2021-03-11 | Ligand Pharm Inc | Antagonista de receptores de endotelina y angiotensina II de bifenilsulfonamida para tratar glomeruloesclerosis y nefropatía inducida por IgA |
ME01858B (me) | 2009-07-17 | 2014-12-20 | Japan Tobacco Inc | Jedinjenje triazolopiridina i njegovo dejstvo kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina |
NZ600400A (en) | 2009-11-06 | 2014-09-26 | Aerpio Therapeutics Inc | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha |
WO2012097331A1 (en) | 2011-01-13 | 2012-07-19 | Fibrogen, Inc. | Methods for increasing reticulocyte hemoglobin content |
MX2013014310A (es) | 2011-06-06 | 2014-01-23 | Akebia Therapeutics Inc | Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer. |
NO2686520T3 (es) | 2011-06-06 | 2018-03-17 | ||
WO2012174256A2 (en) | 2011-06-17 | 2012-12-20 | The Regents Of The University Of Michigan | Dna methylation profiles in cancer |
CA2842730C (en) | 2011-07-22 | 2018-08-21 | Beijing Betta Pharmaceuticals Co., Ltd | Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物 |
NZ753905A (en) | 2013-06-13 | 2020-07-31 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
CA2921005A1 (en) | 2013-08-16 | 2015-02-19 | Ohio State Innovation Foundation | Compositions and methods for modulating dna methylation |
TWI788702B (zh) | 2013-11-15 | 2023-01-01 | 美商阿克比治療有限公司 | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途 |
AU2015209264A1 (en) | 2014-01-23 | 2016-08-04 | Akebia Therapeutics, Inc. | Compositions and methods for treating ocular diseases |
AU2016209126A1 (en) | 2015-01-23 | 2017-08-10 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
AU2016235534A1 (en) | 2015-03-20 | 2017-10-12 | Akebia Therapeutics, Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
US11324734B2 (en) | 2015-04-01 | 2022-05-10 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
WO2019028150A1 (en) | 2017-08-01 | 2019-02-07 | Akebia Therapeutics, Inc. | COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES |
SG11202103191QA (en) | 2018-10-03 | 2021-04-29 | Akebia Therapeutics Inc | Benzimidazole derivative for use in the treatment of inflammatory disorders |
US11524939B2 (en) * | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
-
2014
- 2014-06-04 NZ NZ753905A patent/NZ753905A/en unknown
- 2014-06-04 JP JP2016519543A patent/JP2016521747A/ja active Pending
- 2014-06-04 MX MX2015017229A patent/MX2015017229A/es unknown
- 2014-06-04 EP EP24156067.1A patent/EP4360706A2/en active Pending
- 2014-06-04 SG SG10201910773VA patent/SG10201910773VA/en unknown
- 2014-06-04 KR KR1020217011294A patent/KR102461176B1/ko active Protection Beyond IP Right Term
- 2014-06-04 LT LTEPPCT/US2014/040889T patent/LT3007695T/lt unknown
- 2014-06-04 SG SG11201509998WA patent/SG11201509998WA/en unknown
- 2014-06-04 HR HRP20240319TT patent/HRP20240319T1/hr unknown
- 2014-06-04 CN CN202111479746.1A patent/CN114404414A/zh active Pending
- 2014-06-04 AU AU2014278543A patent/AU2014278543B2/en active Active
- 2014-06-04 RU RU2016100363A patent/RU2705206C2/ru active
- 2014-06-04 CN CN202111479723.0A patent/CN114404413A/zh active Pending
- 2014-06-04 MX MX2020006963A patent/MX2020006963A/es unknown
- 2014-06-04 PE PE2015002603A patent/PE20160194A1/es unknown
- 2014-06-04 US US14/897,849 patent/US11857543B2/en active Active
- 2014-06-04 EP EP14811317.8A patent/EP3007695B1/en active Active
- 2014-06-04 PT PT148113178T patent/PT3007695T/pt unknown
- 2014-06-04 BR BR112015031027A patent/BR112015031027A2/pt not_active Application Discontinuation
- 2014-06-04 RS RS20240271A patent/RS65341B1/sr unknown
- 2014-06-04 RU RU2019134558A patent/RU2019134558A/ru unknown
- 2014-06-04 WO PCT/US2014/040889 patent/WO2014200773A2/en active Application Filing
- 2014-06-04 KR KR1020167000558A patent/KR102373245B1/ko active Protection Beyond IP Right Term
- 2014-06-04 CA CA3151685A patent/CA3151685A1/en active Pending
- 2014-06-04 CN CN201480045048.2A patent/CN105451739A/zh active Pending
- 2014-06-04 FI FIEP14811317.8T patent/FI3007695T3/fi active
- 2014-06-04 KR KR1020227037446A patent/KR102660040B1/ko active IP Right Grant
- 2014-06-04 DK DK14811317.8T patent/DK3007695T3/da active
- 2014-06-04 NZ NZ714963A patent/NZ714963A/en unknown
- 2014-06-04 KR KR1020247012967A patent/KR20240055172A/ko active Application Filing
- 2014-06-04 PE PE2020000452A patent/PE20201496A1/es unknown
- 2014-06-04 NZ NZ753904A patent/NZ753904A/en unknown
- 2014-06-04 SI SI201432066T patent/SI3007695T1/sl unknown
- 2014-06-04 CA CA2914662A patent/CA2914662C/en active Active
- 2014-06-13 TW TW103120661A patent/TWI650126B/zh active
- 2014-06-13 TW TW109141639A patent/TWI791177B/zh active
- 2014-06-13 TW TW111149765A patent/TW202339743A/zh unknown
- 2014-06-13 TW TW107141589A patent/TWI712411B/zh active
-
2015
- 2015-12-07 PH PH12015502738A patent/PH12015502738A1/en unknown
- 2015-12-08 DO DO2015000297A patent/DOP2015000297A/es unknown
- 2015-12-10 IL IL24304715A patent/IL243047B/en active IP Right Grant
- 2015-12-10 ZA ZA2015/09024A patent/ZA201509024B/en unknown
- 2015-12-11 MX MX2022003510A patent/MX2022003510A/es unknown
- 2015-12-11 CL CL2015003602A patent/CL2015003602A1/es unknown
-
2016
- 2016-04-25 HK HK16104721.0A patent/HK1216844A1/zh unknown
-
2018
- 2018-08-17 CL CL2018002372A patent/CL2018002372A1/es unknown
-
2019
- 2019-05-14 JP JP2019091113A patent/JP6612479B2/ja active Active
- 2019-10-30 JP JP2019197138A patent/JP6937812B2/ja active Active
- 2019-10-31 IL IL270335A patent/IL270335B/en active IP Right Grant
-
2020
- 2020-02-07 AU AU2020200903A patent/AU2020200903B2/en active Active
- 2020-09-17 EC ECSENADI202058592A patent/ECSP20058592A/es unknown
- 2020-10-15 PH PH12020551705A patent/PH12020551705A1/en unknown
-
2021
- 2021-02-23 IL IL281058A patent/IL281058B2/en unknown
- 2021-08-31 JP JP2021140772A patent/JP7328291B2/ja active Active
-
2022
- 2022-01-28 AU AU2022200570A patent/AU2022200570B2/en active Active
-
2023
- 2023-08-03 JP JP2023127201A patent/JP2023145717A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015003602A1 (es) | Composiciones y métodos para tratar anemia. | |
SV2017005555A (es) | Composiciones de acido obeticolico y metodos de uso | |
CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
BR112016011065A8 (pt) | composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia | |
EA201690930A1 (ru) | Композиции и способы модуляции фарнезоидных х-рецепторов | |
EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
NI201500142A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos. | |
BR112017005693A2 (pt) | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. | |
EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
MX363457B (es) | Compuestos de sulfonamida heterociclica sustituida utiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1). | |
MX2020003096A (es) | Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif. | |
EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
CL2013002673A1 (es) | Composicion que comprende un polipéptido aislado con actividad inhibidor de nav1.3 y nav1.7; composicion farmacéutica que comprende la composicion antes dicha; metodo para tratar dolor. | |
EA201790576A1 (ru) | Спироциклические ингибиторы катепсина с | |
EA201890331A1 (ru) | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена | |
IN2015DN01151A (es) | ||
MX2019001011A (es) | Compuestos farmaceuticos. | |
MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
DOP2016000120A (es) | Nuevos inhibidores de dgat2 | |
BR112017011476A2 (pt) | composição baseada em aminoácidos para recuperação de fibroelastina em tecidos conjuntivos dérmicos e uso | |
NZ707090A (en) | Synthetic lethality and the treatment of cancer | |
EA201591259A1 (ru) | Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf | |
EA201890075A1 (ru) | Инъецируемые фармацевтические композиции лефамулина | |
CL2016001192A1 (es) | Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas. | |
UY33568A (es) | Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes. |